Plaque psoriasis & psoriatic arthritis patient who are anti-TNFα inadequate responders or patient w/ concomitant moderate to severe plaque psoriasis 300 mg SC inj given as 1 or 2 doses w/ initial dosing at wk 0, 1, 2, 3 & 4, followed by mthly maintenance dosing. Some patient ≥90 kg may derive additional benefit from 300 mg every 2 wk. For some patient, 150 mg may be acceptable.
HS 300 mg SC inj w/ initial dosing at wk 0, 1, 2, 3 & 4, followed by mthly maintenance dosing. Maintenance dose may be increased to 300 mg every 2 wk based on clinical response.
Psoriatic arthritis, AS & nr-axSpA 150 mg SC inj w/ initial dosing at wk 0, 1, 2, 3 & 4, followed by mthly maintenance dosing. May be increased to 300 mg based on clinical response for psoriatic arthritis & AS.
Ped patient ≥6 yr w/ plaque psoriasis or JIA categories of ERA & JPsA SC inj w/ initial dosing at wk 0, 1, 2, 3 & 4, followed by mthly maintenance dosing.
Ped <50 kg 75 mg,
≥50 kg 150 mg, may be increased to 300 mg for ped plaque psoriasis.
Sign Out
 150 mg_mLe923a17a-bf76-4fc0-a4e4-af7200e734a3.GIF)
